Printer Friendly

Akorn, Inc. Announces the Issuance of New Patent Related to Indocyanine Green.

BUFFALO GROVE, Ill. -- Akorn, Inc. today announced that the U.S. Patent and Trademark Office (PTO) has issued U.S. patent number 6,352,663 titled Methods for diagnosing and treating abnormal vasculature using fluorescent dye angiography and dye enhanced photocoagulation.

Dr. Abu Alam, Akorn's Vice President of Research and Development stated, "Indocyanine green (ICG) has great potential for the diagnosis and treatment of choroidal neovascularization (CNV) associated with age related macular degeneration (AMD). The issuance of this patent will further strengthen Akorn's intellectual property position related to ICG and its use in treating AMD."

The patent covers the method for enhancing the clarity of ICG angiograms by employing a relatively high concentration of the dye to precisely identify abnormal vasculatures and targeting a laser to stop the blood flow feeding the CNV. The laser energy is provided to excite the dye as it passes through the blood vessel to maximize the outcome and minimize collateral tissue damage. Essentially, it starves the CNV by a non-invasive method.

Tony Pera, Akorn's president and chief operating officer stated, "ICG is a very important product for Akorn. The issuance of this key patent represents an important milestone for Akorn as it further illustrates our commitment to ICG and the potential it has in the treatment of AMD."

About Akorn, Inc.

Akorn, Inc. manufactures and markets sterile specialty pharmaceuticals, and markets and distributes an extensive line of pharmaceuticals and ophthalmic surgical supplies and related products.

The information contained in this news release, other than historical information, consists of forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those described in such statements. Such statements, including, but not limited to, the timing of acquiring and developing new products, of bringing them on line and deriving revenues and profits from them, as well as the effects of those revenues and profits on the Company's margin and financial position are uncertain because many of the factor affecting the timing of those items are beyond the Company's control. Such statements are based on management's current expectations, but actual results may differ materially due to various factors including risks and uncertainties mentioned or referred to in this press release or in the filings the Company makes with the Securities and Exchange Commission including it annual reports on Form 10-K and its quarterly reports on Form 10-Q.


Contact: Ben J. Pothast, Chief Financial Officer of Akorn, Inc., +1-847-279-6100, or Lisa Carlton-Wilson, Investor Relations of In-Site Communications, Inc. for Akorn, Inc., +1-212-759-3929
COPYRIGHT 2002 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Geographic Code:1USA
Date:Mar 21, 2002
Previous Article:ECI Conference Call Services Sponsors Top Investor Relations Industry Award; Investor Relations Magazine Awards, Recognizing Excellence in Investor...
Next Article:United to Begin Daily Nonstop Service Between Washington Dulles and Oakland; New Service Makes United the Only Carrier to Fly Nonstop Between...

Related Articles
Akorn, Inc. Introduces 'D.E.T.' a New Diagnostic Product.
Akorn, Inc. Announces an Agreement with Ciba Vision to Sell Generic Ocupress Prior to Patent Expiration.
/C O R R E C T I O N -- Photogen Technologies Inc. (OTC Bulletin Board: PHGN)/.
Akorn, Inc. Enters Exclusive Worldwide Cross Licensing Agreement With NovaDAQ Technologies, Inc. For Coronary Artery Bypass Graft Surgery Products.
Akorn, Inc.
Akorn, Inc. Appoints Ben J. Pothast as Vice President of Finance, Chief Financial Officer.
Akorn, Inc. Announces Financing Agreement with a Biotechnology Company to Complete Lyophilization Facility.
Akorn, Inc. Announces Extension of Forebearance Agreement.
Akorn, Inc. Announces Revised Agreement with Novadaq Technologies, Inc.
Akorn, Inc. Receives FDA Approval to Launch Paremyd(R).

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters